Resources

PATH collaborated with the Ministry of Health in Malawi to create an essential spare parts list, determine annual spare part quantities needed, and estimate the cost for the spare parts to facilitate budget and procurement decisions.This analysis suggests that Malawi needs to stock between 23,965 and 73,581 units of spare parts annually to support 12 respiratory care medical device types. The range is driven by the frequency of replacing spare parts, and the variation of spare part costs from local distributors. While providing valuable insights into the spare part requirements for respiratory care devices in Malawi, the study underscores the importance of adequate budgeting and inventory management. The study's findings highlight a significant demand for spare parts within health facilities, suggesting a need for a special annual budget allocation.

Surveys to vaccine and pharmaceutical regulators and manufacturers on endotoxin testing methodsEndotoxin testing is essential for ensuring the safety of injectable pharmaceutical products by detecting potentially harmful bacterial toxins.Traditional gold standard method, the Limulus Amebocyte Lysate (LAL) test, utilizes horseshoe crab blood for endotoxin detection. However, use of horseshoe crab blood led to the decline in horseshoe crab population. It now poses a significant threat to the sustainability of LAL test, impacting the medical field by potentially jeopardizing the safety of pharmaceutical products and posing a significant threat to public health. Advancements in technology have introduced alternatives, notably the recombinant Factor C (rFC) assay, which offers a sustainable and ethical alternative by eliminating the need for horseshoe crab blood.This survey aims to review current endotoxin testing methods and assess the potential for the rFC method to be adopted by manufacturers in Low- and Middle-Income Countries (LMICs).By evaluating the benefits and challenges of rFC technology, this survey seeks to provide valuable insights into how LMIC manufacturers, regulators and stakeholders might navigate the transition to this innovative method, enhancing their testing capabilities while addressing global sustainability and ethical considerations.

Use these slide decks to share the evidence supporting a single-dose regimen of HPV vaccine. Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.

As of August 2024, nearly 60 countries have adopted a single-dose HPV vaccination schedule. This brief summarizes critical study findings, estimated public health impacts, and current recommendations to assist policymakers with decision-making.

"Uniting forces for MNCH advocacy impact: The game changers," the third in our Africa regional MNCH advocacy dialogues series, was held on September 26, 2024.It featured a moderated discussion with panelists from PATH, World Health Organization, Kakamega MNCH Alliance, and the Centre for Reproductive Health and Education. The resources below include the presentation delivered by the panelists and recordings of the webinar in both English and French.